Abionyx Pharma (FRA:609) EPS (Basic): €-0.16 (TTM As of Dec. 2025)


FRA:609 Abionyx Pharma FRA:609
15 GF Score
Price €2.17
GF Value €0.80
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma EPS (Basic)?

Abionyx Pharma FRA:609 +1.17% 15 EPS (Basic) is €-0.16 as of Dec. 2025. GuruFocus rates FRA:609 with a GF Score™ of 15/100 and a GF Value™ of €0.80 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Abionyx Pharma's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.09. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.16.

Abionyx Pharma's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.16.

Abionyx Pharma's EPS without NRI for the six months ended in Dec. 2025 was €-0.09. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.16.

During the past 3 years, the average EPS without NRI Growth Rate was -2.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Abionyx Pharma's highest 3-Year average EPS without NRI Growth Rate was 34.40% per year. The lowest was -41.20% per year. And the median was 15.05% per year.

Abionyx Pharma  (FRA:609) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Abionyx Pharma EPS (Basic) Related Terms

Abionyx Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma EPS (Basic) Chart

Abionyx Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.15 -0.12 -0.13 -0.16

Abionyx Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.06 -0.07 -0.07 -0.09
FRA:609
15GF Score
Abionyx Pharma FRA:609
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Abionyx Pharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.55-0)/35.491
=-0.16

Abionyx Pharma's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.244-0)/35.514
=-0.09

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.16 mean?
Abionyx Pharma (FRA:609) has a EPS (Basic) of €-0.16 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Abionyx Pharma and its competitors.
Is Abionyx Pharma's EPS (Basic) too high?
Abionyx Pharma's current EPS (Basic) is €-0.16. Overall, Abionyx Pharma has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's EPS (Basic) compare to VRTX and REGN?
Abionyx Pharma's EPS (Basic) of €-0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current EPS (Basic) is €-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.80, compared to a current price of €2.17 — trading 171.3% above its estimated fair value. The current EPS (Basic) is €-0.16. Abionyx Pharma's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current EPS (Basic) is €-0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €2.17 is trading 171.3% above its estimated GF Value™ of €0.80. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

  • EPS (Basic): €-0.16
  • GF Value™: €0.80 vs. price of €2.17 (171.3% above fair value)
  • GF Score™: 15/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
15GF Score

Get the complete analysis for FRA:609

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.17
Price
€0.80
GF Value